250 related articles for article (PubMed ID: 25856345)
1. (-)-Liriopein B Suppresses Breast Cancer Progression via Inhibition of Multiple Kinases.
Wang HC; Chang FR; Huang TJ; Kuo CY; Tsai YC; Wu CC
Chem Res Toxicol; 2015 May; 28(5):897-906. PubMed ID: 25856345
[TBL] [Abstract][Full Text] [Related]
2. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
3. Gallic acid abolishes the EGFR/Src/Akt/Erk-mediated expression of matrix metalloproteinase-9 in MCF-7 breast cancer cells.
Chen YJ; Lin KN; Jhang LM; Huang CH; Lee YC; Chang LS
Chem Biol Interact; 2016 May; 252():131-40. PubMed ID: 27087131
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
[TBL] [Abstract][Full Text] [Related]
5. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
Normanno N; De Luca A; Maiello MR; Campiglio M; Napolitano M; Mancino M; Carotenuto A; Viglietto G; Menard S
J Cell Physiol; 2006 May; 207(2):420-7. PubMed ID: 16419029
[TBL] [Abstract][Full Text] [Related]
6. Platycodin D inhibits migration, invasion, and growth of MDA-MB-231 human breast cancer cells via suppression of EGFR-mediated Akt and MAPK pathways.
Chun J; Kim YS
Chem Biol Interact; 2013 Oct; 205(3):212-21. PubMed ID: 23867902
[TBL] [Abstract][Full Text] [Related]
7. Antiangiogenic 1-Aryl-3-[3-(thieno[3,2-b]pyridin-7-ylthio)phenyl]ureas Inhibit MCF-7 and MDA-MB-231 Human Breast Cancer Cell Lines Through PI3K/Akt and MAPK/Erk Pathways.
Machado VA; Peixoto D; Queiroz MJ; Soares R
J Cell Biochem; 2016 Dec; 117(12):2791-2799. PubMed ID: 27152982
[TBL] [Abstract][Full Text] [Related]
8. Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
Bessette DC; Tilch E; Seidens T; Quinn MC; Wiegmans AP; Shi W; Cocciardi S; McCart-Reed A; Saunus JM; Simpson PT; Grimmond SM; Lakhani SR; Khanna KK; Waddell N; Al-Ejeh F; Chenevix-Trench G
PLoS One; 2015; 10(5):e0125232. PubMed ID: 25969993
[TBL] [Abstract][Full Text] [Related]
9. Ethanol Extracts of Dietary Herb,
Kuo CY; Weng TS; Kumar KJS; Tseng YH; Tung TW; Wang SY; Wang HC
Integr Cancer Ther; 2019; 18():1534735419866924. PubMed ID: 31409145
[TBL] [Abstract][Full Text] [Related]
10. Kalopanaxsaponin A inhibits PMA-induced invasion by reducing matrix metalloproteinase-9 via PI3K/Akt- and PKCdelta-mediated signaling in MCF-7 human breast cancer cells.
Park SK; Hwang YS; Park KK; Park HJ; Seo JY; Chung WY
Carcinogenesis; 2009 Jul; 30(7):1225-33. PubMed ID: 19420016
[TBL] [Abstract][Full Text] [Related]
11. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.
Bartucci M; Morelli C; Mauro L; Andò S; Surmacz E
Cancer Res; 2001 Sep; 61(18):6747-54. PubMed ID: 11559546
[TBL] [Abstract][Full Text] [Related]
12. Frondoside A has an anti-invasive effect by inhibiting TPA-induced MMP-9 activation via NF-κB and AP-1 signaling in human breast cancer cells.
Park SY; Kim YH; Kim Y; Lee SJ
Int J Oncol; 2012 Sep; 41(3):933-40. PubMed ID: 22710811
[TBL] [Abstract][Full Text] [Related]
13. Taiwan cobra cardiotoxin III suppresses EGF/EGFR-mediated epithelial-to-mesenchymal transition and invasion of human breast cancer MDA-MB-231 cells.
Tsai PC; Fu YS; Chang LS; Lin SR
Toxicon; 2016 Mar; 111():108-20. PubMed ID: 26774845
[TBL] [Abstract][Full Text] [Related]
14. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Li B; Chang CM; Yuan M; McKenna WG; Shu HK
Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
16. Cardiotoxin III suppresses MDA-MB-231 cell metastasis through the inhibition of EGF/EGFR-mediated signaling pathway.
Tsai PC; Hsieh CY; Chiu CC; Wang CK; Chang LS; Lin SR
Toxicon; 2012 Oct; 60(5):734-43. PubMed ID: 22683533
[TBL] [Abstract][Full Text] [Related]
17. A novel guaiane sesquiterpene derivative, guai-2-en-10α-ol, from Ulva fasciata Delile inhibits EGFR/PI3K/Akt signaling and induces cytotoxicity in triple-negative breast cancer cells.
Pragna Lakshmi T; Vajravijayan S; Moumita M; Sakthivel N; Gunasekaran K; Krishna R
Mol Cell Biochem; 2018 Jan; 438(1-2):123-139. PubMed ID: 28766167
[TBL] [Abstract][Full Text] [Related]
18. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 1-(3-aryl-4-chlorophenyl)-3-(p-aryl)urea derivatives against breast cancer by inhibiting PI3K/Akt/mTOR and Hedgehog signalings.
Li W; Sun Q; Song L; Gao C; Liu F; Chen Y; Jiang Y
Eur J Med Chem; 2017 Dec; 141():721-733. PubMed ID: 29107429
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of berberine against EGFR, ERK1/2, P38 and AKT in MDA-MB231 and MCF-7 breast cancer cells using molecular modelling and in vitro study.
Jabbarzadeh Kaboli P; Leong MP; Ismail P; Ling KH
Pharmacol Rep; 2019 Feb; 71(1):13-23. PubMed ID: 30343043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
